Contineum Therapeutics (CTNM) Cash from Operations (2023 - 2025)
Contineum Therapeutics has reported Cash from Operations over the past 3 years, most recently at 13042000.0 for Q4 2025.
- Quarterly results put Cash from Operations at 13042000.0 for Q4 2025, down 27.84% from a year ago — trailing twelve months through Dec 2025 was 55312000.0 (down 68.4% YoY), and the annual figure for FY2025 was 55312000.0, down 68.4%.
- Cash from Operations for Q4 2025 was 13042000.0 at Contineum Therapeutics, down from 12197000.0 in the prior quarter.
- Over the last five years, Cash from Operations for CTNM hit a ceiling of 40674000.0 in Q2 2023 and a floor of 15661000.0 in Q2 2025.
- Median Cash from Operations over the past 3 years was 9350500.0 (2024), compared with a mean of 5734000.0.
- Peak annual rise in Cash from Operations hit 4.69% in 2024, while the deepest fall reached 120.9% in 2024.
- Contineum Therapeutics' Cash from Operations stood at 10704000.0 in 2023, then rose by 4.69% to 10202000.0 in 2024, then decreased by 27.84% to 13042000.0 in 2025.
- The last three reported values for Cash from Operations were 13042000.0 (Q4 2025), 12197000.0 (Q3 2025), and 15661000.0 (Q2 2025) per Business Quant data.